Enrico Amico

Early defect of transforming growth factor β1 formation in Huntington's disease.

FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.

Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease.

Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.

Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease.

Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models.

Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease.

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.